FTC Warns Of Harms In Mylan Dispute With Sanofi
Federal trade officials have said improper listings of drugs on the U.S. Food and Drug Administration's catalog of approved pharmaceuticals "can cause significant harm to competition," the latest in an intellectual...To view the full article, register now.
Already a subscriber? Click here to view full article